Mosby's 2014 Nursing Drug Reference (74 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

butoconazole vaginal
antifungal

See
Appendix B

 

butorphanol (Rx)

(byoo-tor′fa-nole)

Func. class.:
Opioid analgesic

Chem. class.:
Mixed opioid antagonist, partial agonist

 

Controlled Substance Schedule IV
ACTION:

Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors

USES:

Moderate to severe pain, general anesthesia induction/maintenance, headache, migraine, preanesthesia

Unlabeled uses:
Pruritus

CONTRAINDICATIONS:

Hypersensitivity to product, preservative; addiction (opioid)

Precautions:
Pregnancy (C), breastfeeding, children <18 yr, addictive personality, increased intracranial pressure, respiratory depression, renal/hepatic disease, bowel impaction, CHF, MI

DOSAGE AND ROUTES
Calculator
Moderate-severe pain

• Adult: IM
1-4 mg q3-4hr prn;
IV
0.5-2 mg q3-4hr prn;
INTRANASAL
1 spray in 1 nostril, may give another dose 1-1½ hr
later; repeat if needed 3-4hr after last dose

• Geriatric: IV
1/2 adult dose at 2× the interval;
INTRANASAL
if no relief after 90-120 min, may repeat with 1 spray

Renal/hepatic dose

• Adult: INTRANASAL
max 1 mg followed by 1 mg after 90-120 min;
IM/IV
give 50% of dose (0.5 mg
IV,
1 mg
IM
), do not repeat within 6 hr

Opioid-induced pruritus (unlabeled)

• Adult: INTRANASAL
1 mg (1 spray) in each nostril q4-6hr

Intractable pruritus with inflammatory skin or systemic disease (unlabeled)

• Adult: INTRANASAL
1-4 mg/day

Available forms:
Inj 1, 2 mg/ml; nasal spray 10 mg/ml

Administer:

• 
With antiemetic if nausea, vomiting occur

• 
When pain beginning to return; determine dosage interval according to patient response

Nasal route

• 
Prime before first use, point sprayer away from the face, pump activator 7 times until a fine, wide spray occurs if not used for 48 hr, reprime by pumping 1-2 ×

• 
If more than 1 spray is needed, use other nostril

• 
Do not share with others

• 
Nasal congestion/irritation may occur

IM route

• 
Deeply in large muscle mass

IV direct route

• 
Undiluted at a rate of <2 mg/>3-5 min, titrate to patient response; inject directly in vein or tubing of free-flowing compatible IV inf

Syringe compatibilities:
Atropine, chlorproMAZINE, cimetidine, diphenhydrAMINE, droperidol, fentaNYL, hydrOXYzine, meperidine, methotrimeprazine, metoclopramide, midazolam, morphine, pentazocine, perphenazine, prochlorperazine, promethazine, scopolamine, thiethylperazine

Y-site compatibilities:
Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome (AmBisome), anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefepime, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone phosphate, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, lactated Ringer’s injection, levofloxacin, lidocaine, linezolid injection, LORazepam, magnesium, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed,
penicillin G potassium/sodium, pentazocine, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s injection, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole

SIDE EFFECTS

CNS:
Drowsiness, dizziness, confusion, headache, sedation, euphoria, weakness, hallucinations
, insomnia (nasal)

CV:
Palpitations, bradycardia, hypotension

EENT:
Tinnitus, blurred vision, miosis, diplopia, nasal congestion, unpleasant taste

GI:
Nausea, vomiting, anorexia, constipation, cramps

GU:
Dysuria, urinary retention

INTEG:
Rash, urticaria, bruising, flushing, diaphoresis, pruritus

RESP:
Respiratory depression,
URI, sinusitis

PHARMACOKINETICS

Metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, half-life 2-9 hr, protein binding 80%

IM:
Onset 5-15 min, peak 30-60 min, duration 3-4 hr

INTRANASAL:
Onset within 15 min, peak 1-2 hr, duration 4-5 hr

IV:
Onset 1 min, peak 4-5 min, duration 2-4 hr

INTERACTIONS

 
Increase:
Severe, fatal reactions: MAOIs

Increase:
CNS effects—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants, other CNS depressants

NURSING CONSIDERATIONS
Assess:

• 
For decreasing output; may indicate urinary retention

 
For withdrawal symptoms in opioid-dependent patients; PE, vascular occlusion, abscesses, ulcerations

• 
CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction

• 
Allergic reactions: rash, urticaria

• 
Respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are <10/min

• 
Need for pain medication, physical dependence

Perform/provide:

• 
Storage in light-resistant container at room temp

• 
Safety measures: night-light, call bell within easy reach, assistance with ambulation, especially for geriatric patients

Evaluate:

• 
Therapeutic response: decrease in pain

Teach patient/family:

• 
To report any symptoms of CNS changes, allergic reactions

• 
That physical dependency may result when used for extended periods

• 
That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia

• 
How to use nasal product

• 
To avoid hazardous activities

TREATMENT OF OVERDOSE:

Naloxone HCl (Narcan) 0.2-0.8 mg IV, O
2
, IV fluids, vasopressors

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

Other books

An Act of Love by Nancy Thayer
Shilo's Secret by Stephan, Judith
All the Names by José Saramago
How to Get to Rio by Julie Fison
B008257PJY EBOK by Worth, Sandra
Dragonvein (Book Two) by Brian D. Anderson
The Purity of Vengeance by Jussi Adler-Olsen
The Art of the Devil by John Altman
Shadow of a Dark Queen by Raymond E. Feist
Guardian Ranger by Cynthia Eden